Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

• Pei-Chang Lee,
• I-Cheng Lee,
• Ming-Chih Hou,
• Yi-Hsiang Huang,
• Jiing-Chyuan Luo,
• Chi-Jung Wu,
• Ya-Wen Hung,
• Chieh Ju Lee,
• Chen-Ta Chi,
• Kuo Yu-Lun,
• Shih-Hsuan Chou

Affiliations

Pei-Chang Lee

Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan

I-Cheng Lee

Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan

Ming-Chih Hou

Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Yi-Hsiang Huang

Division of Gastroenterology and Hepatology, Department of Medicine at Taipei Veterans General Hospital and Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

Jiing-Chyuan Luo

6Department of Medicine, National Yang-Ming University, School of Medicine, and Taipei Veterans General Hospital, Taipei, Taiwan

Chi-Jung Wu

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Ya-Wen Hung

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Chieh Ju Lee

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Chen-Ta Chi

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Kuo Yu-Lun

Biotools Co. Ltd, New Taipei City, Taiwan

Shih-Hsuan Chou

Biotools Co. Ltd, New Taipei City, Taiwan